Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm	Recruiting	Phase 1	2026-02-06		NCT07130695

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Rigel Pharmaceuticals	13
Virginia Commonwealth University	122

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Virginia Commonwealth University	Richmond	United States	156

Clinical trials